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Abstract: The blood–brain barrier (BBB) blocks the passage of active molecules from the blood 
which makes drug delivery to the brain a challenging problem. Oral drug delivery using chemically 
modified drugs to enhance their transport properties or remove the blocking of drug transport across 
the BBB is explored as a common approach to address these problems, but with limited success. 
Local delivery of drugs directly to the brain interstitium using implants such as polymeric wafers, 
gels, and catheters has been recognized as a promising alternative particularly for the treatment of 
brain cancer (glioma) and neurodegenerative disorders. The aim of this study was to introduce a 
new solution by engineering a drug-releasing implant for local drug delivery in the brain, based on 
titanium (Ti) wires with titania nanotube (TNT) arrays on their surfaces. Drug loading and drug 
release characteristics of this system were explored using two drugs commonly used in oral brain 
therapy: dopamine (DOPA), a neurotransmitter agent; and doxorubicin (DOXO), an anticancer 
drug. Results showed that TNT/Ti wires could provide a considerable amount of drugs (.170 µg 
to 1000 µg) with desirable release kinetics and controllable release time (1 to several weeks) and 
proved their feasibility for use as drug-releasing implants for local drug delivery in the brain.
Purpose: In this report, a new drug-releasing platform in the form of nanoengineered Ti wires 
with TNT arrays is proposed as an alternative for local delivery of chemotherapeutics in the 
brain to bypass the BBB. To prove this concept, drug loading and release characteristics of 
two drugs important for brain therapy (the neurotransmitter DOPA and the anticancer drug 
DOXO) were explored.
Methods: Titania nanotube arrays on the surface of Ti wires (TNT/Ti) were fabricated using 
a simple anodization process, followed by separate loading of two drugs (DOPA and DOXO) 
inside the nanotube structures. The loading and in vitro release characteristics of prepared TNT/
Ti implants were examined using thermogravimetric analysis (TGA) UV-Vis spectroscopy.
Results: Scanning electron microscopy studies confirmed that well-ordered, vertically aligned, 
densely packed nanotube arrays with an average diameter of 170 nm and length 70 µm were 
formed on the surface of  TNT/Ti wires. TGA results showed a total drug loading of 170 µg and 
1200 µg inside the TNTs for DOPA and DOXO respectively. Two-phase drug release behavior was 
observed including a fast release (burst) for the first 6 hours and a prolonged slow release phase 
for 8 days, both with acceptable dosage and desirable release kinetics. The physical, structural, 
loading and release characteristics of prepared TNT/Ti implants showed several advantages in 
comparison with existing and clinically proved brain implants.
Conclusion: Our results confirmed that TNT/Ti wires can be successfully employed as a   suitable 
platform to release neurotransmitters such as DOPA and anticancer drugs such as DOXO. Hence, 
they are a feasible alternative as drug-releasing implants for local drug delivery in the brain to 
combat neurodegenerative disorders or brain tumors.
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Introduction
To address the limitations of conventional and systematic 
drug delivery such as low drug efficacy, poor bioavailability 
and biodistribution, drug overdose, and high toxicity, a local 
drug delivery system to deliver drugs to specific sites is 
recognized as a promising alternative.1,2 One of the most 
challenging problems in the conventional administration of 
therapeutics is the delivery of drugs to treat diseases associ-
ated with the central nervous system (CNS) and the brain.3,4 
The brain is a specific organ, isolated from general circulation 
and characterized by the presence of relatively impermeable 
endothelial cells with tight junctions, enzymes, receptors and 
active efflux transport mechanisms, known as the blood–brain 
barrier (BBB), which blocks the passage of active molecules 
from the blood compartment to the brain.3 As a result most 
therapeutics have difficulties in effectively reaching the 
targeted sites in the brain, and hence there is an urgent need 
to develop advanced drug delivery platforms that are able to 
bypass this barrier. One approach is to chemically modify 
drugs or drug vectors to enhance their transport properties, or 
use co-drug systems for the inhibition of efflux transporters 
to remove the blocking of drug transport across the BBB.5 
Several drug delivery systems were developed to bypass the 
BBB specifically for the treatment of neurodegenerative dis-
eases (Alzheimer’s disease and Parkinson’s disease) and brain 
cancer, but with limited success.6–8 Also majority of drugs 
do not have the desirable physicochemical characteristics, 
such as high lipid solubility, low molecular size, hydrophilic 
compounds, and/or positive charges, which are necessary to 
allow passage across the BBB.5 These obstacles have resulted 
in an emphasis on developing alternative delivery modalities 
based on local delivery of drugs directly to the brain intersti-
tium, particularly focused on treating brain cancer (glioma) 
and neurodegenerative disorders.9
Local drug delivery systems like cerebral i  nfusion 
methods, polymeric nanoparticles, polymeric wafers or 
gels, catheters, and pumps were extensively explored in 
recent years as promising alternatives for the delivery of 
chemotherapeutic agents into the brain.10–16 The development 
of biodegradable polymer implants (Gliadel R Wafer, MGI 
Pharma, Bloomington, MN) has been approved by the US 
Food and Drug Administration and clinically applied for 
delivering an anticancer drug (carmustine) to the brain. This 
is the only interstitial chemotherapy device currently available 
for the treatment of brain tumors.17,18 The carmustine wafer 
(14.5 mm in diameter and 1 mm thick) containing 7.7 mg of 
drug in biodegradable polymer (poly[bis(p-carboxyphenoxy)-
propane-sebacic acid]) is placed in the surgical cavity around 
the identified tumor and drug is released as a result of polymer 
degradation for several weeks.19 Although the preclinical 
studies have shown modest efficacy, they serve as adequate 
proof of principle to demonstrate that drug-releasing implants 
can safely serve as a medium to bypass the BBB. Conse-
quently, this strategy opens up new opportunities for the 
development of more advanced implants based on this con-
cept using different nanoengineered platforms, and different 
drugs for the treatment of a broad range of brain diseases.
In this work we propose a new solution to engineer 
a drug-releasing implant for local drug delivery in the 
brain, based on titanium (Ti) wires with titania nanotube 
(TNT) arrays on the surface. TNT arrays, formed by a self-
ordering electrochemical anodization process, have been 
widely recognized as a superior platform for local drug 
delivery applications particularly in the bones,20–23 due to 
their excellent biocompatibility, the high surface-to-volume 
ratio, controllable dimensions, tailorable surface chemistry, 
mechanical/chemical stability and proven capability to load 
and release a large amount of drugs. In our previous work we 
demonstrated several strategies for extended release of poorly 
water-soluble drugs with zero-ordered drug release kinetics 
from TNTs using plasma polymer/biopolymer coating and 
polymer micelles as drug nanocarriers.24–28 These approaches 
have demonstrated many advantages for local therapies where 
sustained and extended delivery of drugs is required. Here, 
we propose the application of nanoengineered Ti wires with 
TNT structures on the surface as drug-releasing implants 
for local delivery of chemotherapeutics in the brain. The 
proposed system is schematically presented in Figure 1. The 
TNT/Ti wires are sugested as a brain implant because this 
design provides simplified surgical implementation inside 
the brain. To explore the feasibility of this system as a drug 
carrier for local therapy in the brain, the drug loading and 
release characteristics of two model drugs relevant to treat-
ment of CNS diseases were investigated. The first, dopamine 
(dopamine hydrochloride, DOPA) used as a neurotransmitter 
agent for Parkinson’s and Alzheimer disease and, the second 
doxorubicin (DOXO), a common anticancer drugs for the 
treatment of brain tumors. Both these drugs are currently 
applied intravenously, and their therapeutic action is limited 
as they cannot efficiently cross the BBB to reach the site of 
action inside the brain.
Materials and methods
Materials
High purity (99.7%) titanium (Ti) wires (thickness 0.75 mm) 
supplied by Alfa Aesar (Ward Hill, MA) were used as the 
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substrate materials. Ethylene glycols, ammonium fluoride 
(NH4F), were obtained from Sigma–Aldrich (Sydney, 
Australia). Dopamine hydrochloride and doxorubicin 
were purchased from Sigma-Aldrich and InterPharma 
Pty Ltd (Sydney, Australia) respectively. High purity Milli-Q 
water, ultra-pure grade (18.2 MΩ) sieved through a 0.22 µm 
filter was used for preparation all water solutions through-
out this study.
Preparation of titania nanotube arrays  
on Ti wires (TNT/Ti)
Titanium wires were cut into equal length of 30–40 mm each, 
mechanically polished and cleaned by sonication in acetone 
for 30 minutes prior to anodization. Two anodization steps 
were performed using a specially designed electrochemical 
cell and computer-controlled power supply (Agilent, Santa 
Clara, CA), using previously described procedures.29,30 In 
the first anodization step, a constant voltage of 100 V was 
applied for 1 hour in ammonium fluoride/ethylene glycol 
electrolyte (3% water and 0.3% NH4F) at 20°C. The obtained 
anodic TNT layer was removed (by sonication in methanol), 
leaving the nanotextured titanium surface for the second 
anodization. A second anodization was performed at the 
same voltage at 1–2 hours to yield an ordered array of TNT 
structures on Ti wire.
Drug loading into TNT/Ti wire
Drug solutions of DOPA (0.5% w/v in water) and DOXO 
(0.2% w/v in toluene) were prepared and used for loading into 
TNT/Ti wires. Toluene was selected as a solvent for DOXO 
due to its low water solubility. TNT/Ti wires cut into smaller 
pieces (25 mm or 10 mm of active length with TNTs) were 
fully immersed in the respective DOPA or DOXO solutions 
to ensure drugs were entirely loaded inside the nanotubes. 
The wires were rotated every 2–4 hours during deposition. 
After 1–3 days of loading, the wires were taken out, and 
dried in air and vacuum to ensure the removal of solvent 
from the TNTs. Finally, to remove the excess of loaded drug 
from the TNT surfaces, samples were gently cleaned with 
a soft tissue after wetting with small amount of phosphate 
buffered saline.
Structural characterization of TNT/Ti 
wires
Structural characterization of the prepared TNT/Ti wires 
before and after drug loading and release were performed 
using a field emission scanning electron microscope 
(SEM, Philips XL 30, Philips Research, Amsterdam, The 
  Netherlands). The samples were cut into small   (approximately 
5 mm) pieces, mounted on a holder with double-sided 
  conductive tape and coated with a layer of platinum 3–5 nm 
thick. Images with a range of scan sizes at normal incidence 
and at a 30° angle were acquired from the top, the bottom 
surface and cross-sections.
Drug loading characterization
To quantify the amount of drug loaded inside the TNT/Ti 
wires, thermogravimetric analysis (TGA) which measures 
the mass change (weight loss) in the sample as a function 
of temperature was performed using a Hi-Res Modulated 
TGA 2950, (TA Instruments, New Castle, DE). To find the 
correct decomposition range/peak of both the drugs, TGA 
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Figure 1 Scheme of drug-releasing implants for local delivery of therapeutics in the brain based on Ti wire with titania nanotube (TNT) arrays on the surface generated by 
electrochemical anodization. Dopamine (brain neurotransmitter) and doxorubicin (anticancer drug) were used as model drugs.
Abbreviations: Ti, titanium; TiO2, titanium dioxide; TNT, titania nanotube.
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of the two pure drugs (without solvent) was performed in 
separate experiments. Later the drug-loaded TNT/Ti wire 
was mounted on the platinum pan and heated from 20°C 
to 800°C in the furnace at a scanning rate of 10°C/min 
under nitrogen gas flow (50 mL/min). Only the weight loss 
peaks identifying the particular drug were taken into con-
sideration to calculate the loading amount. Finally the drug 
amount present inside the TNTs was evaluated using the TGA 
analyzing software (Q SeriesTM Thermal Analysis, Universal 
Analysis 2000, TA Instruments).
In vitro drug release characterization
The release of DOPA and DOXO loaded TNT/Ti wires 
was investigated using in vitro studies in 5 mL phosphate 
buffer (pH 7.2), where the amount of released drug was 
measured using UV-Vis spectroscopy. Measurements were 
taken at short intervals during the first 6 hours to monitor 
the initial burst release, followed by repeated measurements 
every 24 hours to monitor the release until the entire drug 
amount was released into the buffer solution. During each 
measurement, an aliquot of 1 mL was placed in a quartz 
cuvette (1 mL working volume, 5 mm path length) and their 
absorbance measured using a Cary 1E spectrophotometer 
(Varian Inc, Palo Alto, CA) to determine the released amount 
of drug based on a preconstructed calibration curve using 
the prominent wavelength of the individual drug, (250 nm 
for DOPA and 253 nm for DOXO. The TNTs samples 
loaded with DOPA were kept in the dark during the experi-
ments to prevent oxidation of the light-sensitive drug. The 
corresponding drug concentrations were then calculated 
from the absorbance values using the calibration curve. 
The drug release experiment for each drug was carried out 
in triplicate.
Results and discussion
Structural characterization  
of TNT/Ti wires
A series of SEM images are presented in Figure 2 to sum-
marize the morphology of prepared TNT/Ti wires. Figure 2A 
presents a photo of the whole TNT/Ti wire (25 mm) and a 
low resolution image of the Ti wire confirming the radial 
growth of TNT films and their complete coverage of the 
A
TNT
surface
Ti/TNT wire
Ti
5 mm
D
 1 µm  1 µm
 200 nm
 2 mm 1 µm
EF
BC
Figure 2 SEM images of titania nanotube (TNT) arrays generated on Ti wires by electrochemical anodization. (A) TNT/Ti wire implant, (B and C) low and high resolution 
image showing fractures of TNT film, (D–F) cross-sectional image and the top TNT surface showing typical nanotube structures.
Abbreviations: SEM, scanning electron microscope; TNT, titania nanotube; Ti, titanium.
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curved Ti wire. The SEM images show randomly dispersed 
vertical cracks (width 1–1.5 µm and .1 mm long) across 
the entire wire length (Figure 2B and C). The formation of 
these cracks is explained by radial growth of TNT film and 
mechanical stress caused by volume extension of the formed 
TNT oxide layer on the circular surface of the Ti wire. These 
cracks were not observed on TNT films grown on planar Ti 
surfaces, but their presence on wires did not significantly 
change the mechanical stability and rigidity of the TNT 
films. A high-resolution SEM images of the top surface and 
cross-sections of the TNT layer show a vertically aligned 
and densely packed array of uniform nanotubes with diam-
eter of 170 ± 10 nm and length 70 ± 2 µm, across the entire 
structure (Figure 2D and E). These structural characteristics 
suggest that the TNT platforms are ideal for development 
of drug-releasing implants for local drug delivery applica-
tions. In particular, their wire form and their size (0.75 mm 
dia × 10–20 mm length) offers considerable advantages for 
brain implants in comparison with commercial large polymer 
discs (14.5 mm diameter, Gliadel R Wafer, MGI Pharma). 
TNT/Ti wires can enter narrow gaps and occupy minimal 
space without obstruction of the brain tissues, potentially 
allowing simpler surgical procedures during implantation 
and the removal of implants.
Drug loading characteristics  
of   TNT/Ti wires
TGA of the TNT/Ti wires was performed to confirm that 
drugs were successfully loaded into the nanotube structures 
and to determine the amount of loading. Figure 3 shows 
thermograms of the total weight loss of the TNT/Ti wires 
loaded with DOPA and DOXO. Since Ti and titanium oxide 
are thermally stable up to 2500°C to 3000°C respectively, 
they do not undergo any changes in the furnace, so the 
observed weight loss is used to determine the loaded drug 
mass inside the TNTs. A one-step decrease in the thermogram 
was obtained which has the characteristic range matching 
the decomposition temperature of DOPA and DOXO. TGA 
results show total drug loadings of 170 µg and 1200 µg for 
DOPA and DOXO respectively in prepared TNT/Ti wire. 
These drugs have considerably different dosages recom-
mended for systematic administration and these differences 
in their loading in TNTs were achieved using different load-
ing conditions (drug concentration, loading time and post-
loading washing). Particularly, for the anticancer drug DOXO 
to be effective against cancer cells it is critical to have high 
concentrations (.300 mg/m2). In comparison with commer-
cial brain implants in the form of polymer disc (Gliadal R, 
MGI Pharma), about 4–5 implants with TNT/Ti wires (length 
15 mm) are required to have the same drug loading   capacity 
(.7 mg). However, the drug loading capacity of TNT/Ti 
wires can further be optimized by fabrication processes to 
increase nanotube dimensions (selecting appropriate elec-
trolyte, voltage and time), by surface modifications, and by 
selecting the appropriate size/shape of the implant (wires, 
needles, plates or discs). Hence it is possible to customize 
TNT/Ti platforms to meet specific requirements for implant-
able drug delivery in the brain depending on the required 
dosage, properties of drugs, surgery requirements, and the 
the time of proposed brain therapy.18,19,31,32
In vitro drug release of DOPA and 
DOXO from TNT/Ti wires
Drug release profiles and characteristics of DOPA and 
DOXO loaded into TNT/Ti wire are presented in Figure 4 
and Table 1. The drug release kinetics can be described 
in two phases, showing an initial burst release dur-
ing the first 6 hours, followed by the second stage with 
slow release of the remaining drug. In the burst release 
phase, about 60% (100 µg) of DOPA and 25% (300 µg) 
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Figure 3 Thermogravimetric (TGA) graphs showing drug loading of (A) dopamine and (B) doxorubicin into TNT/Ti wire.
Abbreviations: TGA, thermogravimetric analysis; TNT, titania nanotube; Ti, titanium.
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Table 1 Drug release characteristics of two drugs (dopamine and doxorubicin) from TNT/Ti wire showing their drug loading and 
release characteristics (% and mass) during burst and 8-days release period
Drug loaded into  
TNT/Ti
Amount
loaded
drug
Cumulative drug release (% and μg) Rate of drug release
6 hours 2 days 4 days 8 days Burst release After burst 
release
Dopamine 170 µg 60%
100 µg
70%
120 µg
80%
135 µg
100%
170 µg
17 µg/hour 9 µg/day
Doxorubicin 1200 µg 25%
300 µg
36%
435 µg
50%
620 µg
100%
1200 µg
50 µg/hour 112 µg/day
Abbreviations: TNT, titania nanotube; Ti, titanium.
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Figure 4 Drug release graphs showing cumulative release (% and mass) from TNTs/Ti implants for (A and B) dopamine and (C and D) doxorubicin. Both total and burst 
releases are presented.
Abbreviations: TNT, titania nanotube; Ti, titanium.
of DOXO was released (Figure 4B and D). The fast initial 
release accounts for the fast diffusion of the drug molecules 
physisorbed on the top and upper channels of the TNTs, 
as a result of the high concentration gradient at the TNT 
interface with the bulk phosphate buffer solution. The dif-
ference in the release rate of the two drugs can be explained 
by differences in their solubility in buffer solution, which 
influences their diffusion rate into the bulk solution. Water-
solubilities of DOXO and DOPA are 10 mg/mL and 600 mg/
mL   respectively. Also the smaller size and molecular weight 
of DOPA (molecular weight, MW = 189.64 g/moL) as com-
pared to DOXO (MW = 543.5 g/mol) resulted in its faster 
uptake from the TNTs into the buffer solution.
In the second phase, different drug release kinetics 
were observed from TNT/Ti, with very slow and linearly 
increasing cumulative release over a period of 8 days 
  (Figure 4A and C). The release mechanism of this phase is 
diffusion-controlled and it applies to the whole nanotube 
structure, reaching down its entire depth to 70 µm. Again 
slight differences between DOPA and DOXO were observed. 
Considering the high surface area and long capillary-like 
tubular structures of TNT, the diffusion of drug molecules to 
the buffer solution can be described as a surface-dependent 
phenomenon. The best-fitting model to the DOXO release 
data was observed using Higuchi and zero-order release, 
which describe drug release from an insoluble matrix.33 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2074
Gulati et alInternational Journal of Nanomedicine 2012:7
The square root of a time-dependent process is based on 
Fickian diffusion law where the diffusion-controlled release 
rate of drug molecules decreases as a function of time due to 
a reduction in the concentration gradient.33 This behavior can 
be explained by the influence of several parameters includ-
ing low drug solubility, larger molecular size, and chemistry. 
DOXO molecules have a higher number of OH groups and 
one positively charged amino group, which could interact with 
the TNT surface in different ways, including hydrogen bond-
ing and electrostatic interactions, and causing their slower 
release from the nanotube structures. Pharmaceutical dosage 
following a zero-ordered pattern is the ideal profile for drug 
release, because it provides the same amount of drug elution 
per unit of time. These results confirmed that TNT/Ti wire 
can be successfully employed as a suitable drug-releasing 
platform for local delivery of CNS transmitters such as 
DOPA and anticancer drugs such as DOXO, to combat brain 
neurodegenerative disorders and brain tumors with accept-
able dosage and predictable release kinetics.18,32,34,35
Our results demonstrated that the drug release into 
the local environment during this time was constant, with 
a value of about 9 µg and 112 µg per day for DOPA and 
DOXO respectively. By controlling the dimensions of TNT 
structures (diameter and length), this local concentration 
can be controlled and tuned to fit the optimal therapeutic 
window for the treatment of brain cancer or neurodegen-
erative diseases.4,34,35 The general approach for brain cancer 
treatments using implantable devices requires a large drug 
loading and constant release over extended periods (5–6 
weeks). To address this problem, we recently introduced 
several approaches to considerably extend drug release from 
TNTs prepared on planar surfaces using polymer micelles and 
polymer coatings (plasma polymers, chitosan, poly[lactic-co-
glycolic acid]).24–28 These approaches can be incorporated on 
the wire implants to achieve a long and sustained release of 
specific therapeutics with desired concentration and zero-
order kinetics for more than 4–6 weeks.
Conclusion
This study presents the fabrication of titanium wires with 
titania nanotube arrays and explores their drug loading and 
release characteristics for two drugs, DOPA: a neurotransmit-
ter agent and DOXO: an anticancer drug, both important for 
local and implantable drug delivery in the brain. TNTs on Ti 
wire were fabricated by a simple and scalable nanofabrica-
tion technology based on an electrochemical anodization 
process, with ability to tune dimensions to load substantial 
amounts of  brain therapeutic drugs (.1 mg per implant). 
It is proposed that these tiny and biocompatible wire implants 
can easily be inserted in the brain using microsurgery and 
provide considerable advantages in comparison with existing 
clinically proven brain implants. These advantages include: 
appropriate shape (needles and wires), which requires less 
invasive s  urgery; loading/release of water-soluble and 
insoluble drugs or drug-carriers; tailorable drug release 
characteristics including sustained and stimulated release; 
and a wide applications for different brain therapies (eg, neu-
rodisorders and cancer). Future investigations are necessary 
to prove the in vivo performance of these implants.
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